会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • Allergy inhibitor compositions and kits and methods of using the same
    • 过敏抑制剂组合物及其使用方法
    • US20070166335A1
    • 2007-07-19
    • US11644435
    • 2006-12-22
    • Bin WangHuali JinYoumin KangHsien-Jue ChuTerry Kaleung Ng
    • Bin WangHuali JinYoumin KangHsien-Jue ChuTerry Kaleung Ng
    • A61K39/35A61K48/00
    • A61K39/35A61K39/0003A61K39/0005A61K39/0008A61K2039/53A61K2039/57
    • Compositions and kits for inhibiting an allergic response against an allergenic protein are disclosed. The compositions comprise a eukaryotic cell expression vector containing nucleotide sequences encoding an allergenic protein or a polypeptide that comprises an antigenic epitope of said allergenic protein; and an allergenic protein or a polypeptide that comprises an antigenic epitope of the allergenic protein. The kits comprise a first container which comprises a eukaryotic cell expression vector containing nucleotide sequences encoding an allergenic protein or a polypeptide that comprises an antigenic epitope of the allergenic protein and a second container which comprises an allergenic protein or a polypeptide that comprises an antigenic epitope of said allergenic protein. Compositions and kits for inhibiting an allergic response against an flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed. Methods if using such compositions and kits are also disclosed.
    • 公开了抑制对变应原性蛋白质的过敏反应的组合物和试剂盒。 所述组合物包含含有编码过敏原蛋白或包含所述变应原蛋白的抗原表位的多肽的核苷酸序列的真核细胞表达载体; 以及包含过敏原蛋白的抗原表位的变应原蛋白或多肽。 所述试剂盒包括第一容器,其包含含有编码过敏原蛋白的核苷酸序列的真核细胞表达载体或包含过敏原蛋白的抗原表位的多肽,以及第二容器,其包含过敏原蛋白或包含抗原表位的多肽 说过敏性蛋白质。 用于抑制针对跳蚤过敏原蛋白质的过敏反应的组合物和试剂盒; 猫过敏原蛋白; 犬过敏蛋白; 尘螨过敏原蛋白; 花生过敏蛋白; 日本雪松过敏蛋白; 并且公开了热带炎热带炎性过敏蛋白。 还公开了使用这些组合物和试剂盒的方法。
    • 5. 发明授权
    • Allergy inhibitor compositions and kits and methods of using the same
    • 过敏抑制剂组合物及其使用方法
    • US08349333B2
    • 2013-01-08
    • US11644435
    • 2006-12-22
    • Bin WangHuali JinYoumin KangHsien-Jue ChuTerry Kaleung Ng
    • Bin WangHuali JinYoumin KangHsien-Jue ChuTerry Kaleung Ng
    • A61K38/00A61K39/00A61K39/35A61K39/36C07H21/04C12N1/20C12N15/00C12P15/00C12P21/06
    • A61K39/35A61K39/0003A61K39/0005A61K39/0008A61K2039/53A61K2039/57
    • Compositions and kits for inhibiting an allergic response against an allergenic protein are disclosed. The compositions comprise a eukaryotic cell expression vector containing nucleotide sequences encoding an allergenic protein or a polypeptide that comprises an antigenic epitope of said allergenic protein; and an allergenic protein or a polypeptide that comprises an antigenic epitope of the allergenic protein. The kits comprise a first container which comprises a eukaryotic cell expression vector containing nucleotide sequences encoding an allergenic protein or a polypeptide that comprises an antigenic epitope of the allergenic protein and a second container which comprises an allergenic protein or a polypeptide that comprises an antigenic epitope of said allergenic protein. Compositions and kits for inhibiting an allergic response against an flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed. Methods if using such compositions and kits are also disclosed.
    • 公开了抑制对变应原性蛋白质的过敏反应的组合物和试剂盒。 所述组合物包含含有编码过敏原蛋白或包含所述变应原蛋白的抗原表位的多肽的核苷酸序列的真核细胞表达载体; 以及包含过敏原蛋白的抗原表位的变应原蛋白或多肽。 所述试剂盒包括第一容器,其包含含有编码过敏原蛋白的核苷酸序列的真核细胞表达载体或包含过敏原蛋白的抗原表位的多肽,以及第二容器,其包含过敏原蛋白或包含抗原表位的多肽 说过敏性蛋白质。 用于抑制针对跳蚤过敏原蛋白质的过敏反应的组合物和试剂盒; 猫过敏原蛋白; 犬过敏蛋白; 尘螨过敏原蛋白; 花生过敏蛋白; 日本雪松过敏蛋白; 并且公开了热带炎热带炎性过敏蛋白。 还公开了使用这些组合物和试剂盒的方法。
    • 8. 发明授权
    • Mycoplasma hyopneumoniae bacterin vaccine
    • 肺炎支原体疫苗疫苗
    • US07169394B2
    • 2007-01-30
    • US11318983
    • 2005-12-27
    • Hsien-Jue ChuWumin LiZhichang Xu
    • Hsien-Jue ChuWumin LiZhichang Xu
    • A61K39/295
    • A61K9/0024A61K39/0241A61K39/12A61K39/145A61K39/39A61K47/06A61K47/10A61K47/32A61K2039/521A61K2039/525A61K2039/552A61K2039/55555A61K2039/55566A61K2039/70C12N7/00C12N2760/16134Y02A50/48
    • The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA. In another embodiment, the invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.
    • 本发明提供了一种改良的猪肺炎支原体疫苗组合物,其在单次给药后有利地提供免疫感染。 组合物包含灭活的猪肺炎支原体疫苗和佐剂混合物,其组合在单次施用后提供对猪肺炎支原体感染的免疫,并引起对猪肺炎支原体菌苗特异性的免疫应答,并且包括细胞介导的免疫和局部(分泌型IgA )免疫力。 在优选的实施方案中,佐剂混合物包含丙烯酸聚合物,最优选的是CARBOPOL,以及可代谢的油如一种或多种不饱和萜烯烃,优选角鲨烯或角鲨烷的混合物,以及聚氧乙烯 - 聚氧丙烯嵌段共聚物 作为PLURONIC(R)。 疫苗组合物可以任选地包括防腐剂,优选硫柳汞和/或EDTA。 在另一个实施方案中,本发明提供了改进的猪肺炎支原体疫苗组合物,其有利地在单次施用后提供免疫感染,并且包含灭活的猪肺炎支原体菌苗和佐剂或佐剂混合物,其组合提供猪肺炎支原体 单次给药后感染,并引起特异于猪肺炎支原体菌的免疫应答,并与其他疫苗组分结合使用,包括细胞介导的免疫和局部(分泌型IgA)免疫。
    • 10. 发明授权
    • Recombinant feline Immunodeficiency virus subunit vaccines employing
baculoviral-expressed envelope glycoproteins derived from isolate
NCSU-1 and their use against feline immunodeficiency virus infection
    • 重组猫免疫缺陷病毒亚单位疫苗,其使用衍生自分离株NCSU-1的杆状病毒表达的包膜糖蛋白及其对猫免疫缺陷病毒感染的用途
    • US5849303A
    • 1998-12-15
    • US481700
    • 1995-06-07
    • Terri WasmoenHsien-Jue Chu
    • Terri WasmoenHsien-Jue Chu
    • A61K39/00C07K14/155A61K39/12A61K39/21C07H21/04C12N15/00
    • C07K14/005A61K39/00C12N2710/14143C12N2740/15022
    • The present invention pertains to the prevention or lessening of disease in cats caused by Feline Immunodeficiency Virus (FIV). Prevention or lessening of disease is understood to mean the amelioration of any symptoms, including immune system disruptions, that result from FIV infection. The invention provides recombinant proteins produced in a baculovirus expression system having at least one internal gene comprising a DNA sequence that encodes either the entire FIV env region (ENV-ABC), or a DNA sequence consisting of viral nucleotides 6252-8469 of FIV env (ENV-AB), a DNA sequence consisting of viral nucleotides 6252-6722 and 8264-9140 of FIV env (ENV-AC), or immunogenic fragments of any of the foregoing either singly or in combination. By immunogenic fragment is meant any portion of the coding sequence of FIV env polypeptides that induces a beneficial immune response in cats. In another embodiment, the invention encompasses vaccines that comprise one or more of the baculovirus-expressed recombinant FIV proteins described above, with a pharmaceutically acceptable carrier or diluent and a pharmaceutically acceptable adjuvant. In yet another aspect, the invention provides methods for preventing or lessening disease caused by FIV, which is carried out by administering to a feline in need of such treatment the vaccines described above.
    • 本发明涉及由猫免疫缺陷病毒(FIV)引起的猫的疾病的预防或减轻。 理解疾病的预防或减轻意味着由FIV感染引起的任何症状(包括免疫系统中断)的改善。 本发明提供了在杆状病毒表达系统中产生的重组蛋白,其具有至少一个内部基因,其包含编码整个FIV env区域(ENV-ABC)的DNA序列或由FIV env的病毒核苷酸6252-8469组成的DNA序列 ENV-AB),由FIV env(ENV-AC)的病毒核苷酸6252-6722和8264-9140组成的DNA序列,或任何前述任一种的免疫原性片段单独或组合。 免疫原性片段是指在猫中诱导有益的免疫应答的FIV env多肽的编码序列的任何部分。 在另一个实施方案中,本发明包括包含一种或多种上述杆状病毒表达的重组FIV蛋白与药学上可接受的载体或稀释剂和药学上可接受的佐剂的疫苗。 另一方面,本发明提供了预防或减轻由FIV引起的疾病的方法,其通过向需要这种治疗的猫科动物施用上述疫苗来进行。